# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
SON-1010 is a targeted immune activation cancer therapy designed to turn ‘cold' tumors ‘hot'Topline safety data of SB10...
Chardan Capital analyst Keay Nakae maintains Sonnet BioTherapeutics (NASDAQ:SONN) with a Buy and maintains $30 price target.
Preclinical data has demonstrated the potential of SON-1210, the first albumin-binding bifunctional IL-12/IL-15 fusion protein,...
https://ppubs.uspto.gov/dirsearch-public/print/downloadBasicPdf/20240269236?requestToken=eyJzdWIiOiI2NjBiODI3My0yYzg0LTQ2ZDItYT...
Sonnet BioTherapeutics (NASDAQ:SONN) reported quarterly losses of $(0.70) per share which beat the analyst consensus estimate o...
Data indicates that SON-080 was well-tolerated at both doses, with no evidence of a pro-inflammatory cytokine responsePain and ...